- Home
- DOYU vs ACIU Comparison
DOYU vs ACIU Comparison
Compare DOYU & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- ACIU
- Stock Information
- Founded
- DOYU 2014
- ACIU 2003
- Country
- DOYU China
- ACIU Switzerland
- Employees
- DOYU N/A
- ACIU N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- DOYU Technology
- ACIU Health Care
- Exchange
- DOYU Nasdaq
- ACIU Nasdaq
- Market Cap
- DOYU 246.3M
- ACIU 213.3M
- IPO Year
- DOYU 2019
- ACIU 2016
- Fundamental
- Price
- DOYU $8.28
- ACIU $2.15
- Analyst Decision
- DOYU Hold
- ACIU Strong Buy
- Analyst Count
- DOYU 1
- ACIU 1
- Target Price
- DOYU $7.00
- ACIU $12.00
- AVG Volume (30 Days)
- DOYU 78.3K
- ACIU 124.1K
- Earning Date
- DOYU 08-18-2025
- ACIU 08-05-2025
- Dividend Yield
- DOYU 238.73%
- ACIU N/A
- EPS Growth
- DOYU N/A
- ACIU N/A
- EPS
- DOYU N/A
- ACIU N/A
- Revenue
- DOYU $586,290,301.00
- ACIU $36,362,036.00
- Revenue This Year
- DOYU N/A
- ACIU N/A
- Revenue Next Year
- DOYU N/A
- ACIU $533.21
- P/E Ratio
- DOYU N/A
- ACIU N/A
- Revenue Growth
- DOYU N/A
- ACIU 86.71
- 52 Week Low
- DOYU $5.68
- ACIU $1.43
- 52 Week High
- DOYU $19.30
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- DOYU 57.64
- ACIU 50.42
- Support Level
- DOYU $7.90
- ACIU $2.05
- Resistance Level
- DOYU $8.59
- ACIU $2.19
- Average True Range (ATR)
- DOYU 0.43
- ACIU 0.16
- MACD
- DOYU 0.04
- ACIU -0.01
- Stochastic Oscillator
- DOYU 76.43
- ACIU 23.91
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.